Table 1 Baseline characteristics of study patients
|  | N = 29 |
|---|---|
Median age (IQR)—years | 45 (36–56) |
Female gender—n (%) | 18 (62) |
Comorbidities—n (%) |  |
 Hypertension | 1 (3.4%) |
 Dyslipidemia | 3 (10.3%) |
 Obesity | 3 (10.3%) |
Immunosuppression | 2 (6.8%) |
Pneumonia COVID-19—n (%) | 15 (51.7%) |
COVID-19 severity—n (%) |  |
 Mild | 16 (55%) |
 Moderate | 6 (20%) |
 Severe | 7 (24%) |
Antiviral treatment—n (%) | 19 (65%) |
COVID-19 severity and having received antiviral treatment—n (%) |  |
 Mild | 6 (37.5%) |
 Moderate | 6 (100%) |
 Severe | 7 (100%) |
Type antiviral treatment—n (%) |  |
 lpv/r | 15 (78%) |
 HCQ | 19 (100%) |
 Azm | 3 (15%) |
 lpv/r + HCQ | 15 (78%) |
 HCQ + Azm | 3 (15%) |
 Glucocorticoids | 2 (10%) |